First Patient Receives Stem Cell Therapy in Groundbreaking Huntington's Disease Trial
UC Irvine has launched the world's first embryonic stem cell-derived clinical trial for Huntington's disease, offering new hope for a condition with very few treatment options.
6/30/2026
UCI Health has opened the world's first in-human clinical trial using embryonic stem cell-derived neural stem cells to treat Huntington's disease, a fatal genetic disorder that gradually destroys brain cells. The first patient received the treatment in May via a six-hour surgical procedure, with no serious damaging events reported so far. The phase 1b/2a trial will enroll 21 participants total and is funded by a $12 million grant from the California Institute of Regenerative Medicine. Researchers hope the therapy can protect and replace brain cells, potentially slowing the disease's progression.
My perspective: This trial represents a meaningful step forward for a disease that currently has no way to slow its progression, with stem cell science backed by years of peer-reviewed research and regulatory oversight. It's still early (phase 1b/2a trials are primarily about safety, not proven efficacy), so it's worth watching how results unfold before drawing conclusions about real-world impact. However, hopefully this will eventually lead to a future treatment.
References
“First Patient Receives Neural Stem Cell Therapy in Groundbreaking UCI Health Huntington’s Disease Clinical Trial – UC Irvine News.” University of California, Irvine, news.uci.edu/2026/06/23/first-patient-receives-neural-stem-cell-therapy-in-groundbreaking-uci-health-huntingtons-disease-clinical-trial/. Accessed 29 June 2026.
Subscribe to our newsletter
Receive weekly updates on recent cord blood banking and stem cell news.